Target Price | $1.00 |
Price | $0.62 |
Potential |
61.03%
register free of charge
|
Number of Estimates | 2 |
2 Analysts have issued a price target Lyell Immunopharma Inc 2025 .
The average Lyell Immunopharma Inc target price is $1.00.
This is
61.03%
register free of charge
$1.00
61.03%
register free of charge
$1.00
61.03%
register free of charge
|
|
A rating was issued by 4 analysts: 0 Analysts recommend Lyell Immunopharma Inc to buy, 3 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lyell Immunopharma Inc stock has an average upside potential 2025 of
61.03%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 0.13 | 0.04 |
99.85% | 69.85% | |
EBITDA Margin | -177,292.31% | -506,558.79% |
85,517.98% | 185.72% | |
Net Margin | -183,539.08% | -530,136.73% |
81,763.20% | 188.84% |
5 Analysts have issued a sales forecast Lyell Immunopharma Inc 2024 . The average Lyell Immunopharma Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Lyell Immunopharma Inc EBITDA forecast 2024. The average Lyell Immunopharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Lyell Immunopharma Inc Analysts have issued a net profit forecast 2024. The average Lyell Immunopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.93 | -0.81 |
25.68% | 12.90% | |
P/E | negative | |
EV/Sales | negative |
2 Analysts have issued a Lyell Immunopharma Inc forecast for earnings per share. The average Lyell Immunopharma Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Lyell Immunopharma Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Lyell Immunopharma Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.